Hyundai Pharmaceutical Co Ltd

Hyundai Pharmaceutical Co Ltd maintains a debt-to-equity ratio of 0.51, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 1.58, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. Free cash flow stands at 957,221,860 KRW, while operating cash flow is negative at -1,420,742,900 KRW, reflecting a cash outflow from operations.

Profitability metrics show a return on equity (ROE) of 1.3% and a return on assets (ROA) of 0.68%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is generating relatively modest returns for its shareholders and asset base. Gross profit of 18,928,395,420 KRW and operating income of 1,428,330,220 KRW indicate a narrow margin structure, which may be a concern in a competitive industry where cost control is critical.

The company's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess the geographic or product concentration of its business. However, the lack of detailed segment reporting may obscure potential vulnerabilities in specific markets or product categories.

Looking ahead, the company's growth trajectory is not explicitly outlined in the available data. Historical revenue of 43,880,589,210 KRW provides a baseline, but without forward-looking guidance or a clear growth strategy, it is challenging to assess the company's potential for expansion. The absence of a detailed outlook may reflect either a conservative approach or a lack of public disclosure.

Risk factors include a liquidity risk due to a negative net cash position after subtracting total debt, which could limit the company's ability to fund operations or invest in growth opportunities. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. However, the company's capital structure and financial flexibility should be closely monitored, especially in light of its negative operating cash flow.

Recent events and filings do not provide specific details on material developments, but the company's financial snapshot and risk assessment suggest a need for continued scrutiny of its liquidity and profitability. The absence of recent significant events or disclosures may indicate a stable but unremarkable operational environment.

Hyundai Pharmaceutical Co Ltd (004310.KS) has undergone a significant update to its corporate taxonomy, now formally classified under the "Pharmaceuticals & Medical Research" activity within the broader "Healthcare" economic sector. This reclassification represents a medium-severity change in the company's profile, establishing a clearer definition of its operational focus for investors and analysts tracking the healthcare industry. Alongside the sectoral update, the company's risk assessment framework has been populated with new data points. The dilution risk is now assessed as "low," indicating a stable capital structure with minimal threat of share value erosion from new issuances. This assessment provides a baseline for evaluating the company's equity stability, although the specific metrics driving this classification are not detailed in the current data. Conversely, the liquidity risk has been flagged as "medium," suggesting potential constraints or variability in the company's ability to meet short-term obligations or trade volume expectations. This medium-severity risk factor contrasts with the low dilution risk, highlighting a nuanced financial profile where capital preservation appears strong, but immediate market fluidity or cash flow dynamics require closer monitoring. The company currently reports zero analysts, officers, index memberships, and top holders in the available dataset, which may reflect limited public disclosure or a private holding structure. These structural details, combined with the new risk and taxonomy classifications, offer a foundational but sparse view of Hyundai Pharmaceutical's current standing, necessitating further data to fully contextualize its market position. [doc:004310.ks-ha-financials]

Net income surged 537.7% year-over-year to KRW 2.5 billion, signaling a strong recovery in profitability.

Operating income jumped 2,406.1% to KRW 4.2 billion, demonstrating significant improvement in core operational efficiency.

Revenue grew 9.1% year-over-year to KRW 191.8 billion, indicating consistent top-line expansion in the latest fiscal year.

Free cash flow improved by 99.9% year-over-year, nearly eliminating the previous year's negative cash flow position.

Gross profit reached KRW 79.6 billion, maintaining a robust gross margin despite fluctuations in operating expenses.

The company faces high credit risk, suggesting potential difficulties in meeting financial obligations or securing favorable financing.

Cash conversion is in the bottom quartile of the pharmaceutical cohort, indicating poor ability to turn earnings into cash.

Debt-to-equity ratio of 0.51 is significantly higher than the cohort median of 0.18, implying elevated financial leverage.

Operating margin of 3.26% trails the pharmaceutical cohort median of 5.6%, reflecting weaker operational profitability relative to peers.

Return on equity of 1.3% is well below the cohort median of 2.92%, indicating inefficient use of shareholder capital.